Anemia in Cancer

References

• Price V E, Greenfield R E. Anemia in cancer. Adv Cancer Res 1958; 5: 199–200
   PubMed Web of Science ®Google Scholar
• Morrison M. An analysis of the blood picture in 100 cases of malignancy. J Lab Clin Med 1932; 17: 1071–1093
   Google Scholar
• Hyman G A. Anemia in malignant neoplastic disease. J Chron Dis 1963; 16: 645–666
   PubMedGoogle Scholar
• Korbitz B C. Mechanism and management of anemia in malignant disease. J Am Geriatr Soc 1971; 19: 41–50
   PubMed Web of Science ®Google Scholar
• Levy A B. Mechanism of anemia in cancer. Med Clin North Am 1956; 857–870
   PubMed Web of Science ®Google Scholar
• Fidler I J, Hart I R. Biological diversity in metastatic neoplasms: Origin and implications. Science 1982; 217: 998–1003
   PubMed Web of Science ®Google Scholar
• Cartwright G E, Lee G R. The anemia of chronic disorders. Br J Haematol 1971; 21: 147–152
   PubMed Web of Science ®Google Scholar
• Lee G R. The anemia of chronic disease. Seminars Hematol 1983; 20: 61–80
   PubMed Web of Science ®Google Scholar
• Bentley D P. Anaemia and chronic disease. Clin Haematol 1982; 11: 465–479
   PubMedGoogle Scholar
• Ward H P, Kurnick J E, Pisarczyk M J. Serum level of erythropoietin in anemias associated with chronic infection, malignancy, and primary hematopoietic disease. J Clin Invest 1971; 50: 332–335
   PubMed Web of Science ®Google Scholar
• Zucker S, Friedman S, Lysik R M. Bone marrow erythropoiesis in anemia of infection, inflammation and malignancy. J Clin Invest 1974; 53: 1132–1138
   PubMed Web of Science ®Google Scholar
• Douglas S W, Adamson J W. The anemia of chronic disorders: Studies of marrow regulation and iron metabolism. Blood 1975; 45: 55–65
   PubMed Web of Science ®Google Scholar
• Freireich E J, Miller A, Emerson C P, et al. The effect of inflammation on the utilization of erythrocyte and transferrin bound radioiron for red cell production. Blood 1957; 12: 972–983
   PubMed Web of Science ®Google Scholar
• Fillet G, Cook J D, Finch C A. Storage iron kinetics. VII. A biologic model for reticuloendothelial iron transport. J Clin Invest 1974; 53: 1527–1533
   PubMed Web of Science ®Google Scholar
• Finch C A, Deubelbeiss K, Cook J D, et al. Ferrokinetics in man. Medicine 1970; 49: 17–53
   PubMed Web of Science ®Google Scholar
• Kumar R. Mechanism of anaemia of chronic infection-estimate of labile iron pool and interpretation of ferrokinetic data. Indian J Med Res 1979; 70: 455–462
   PubMed Web of Science ®Google Scholar
• Haurani F I, Young K, Tocantin L. Reutilization of iron in anemia complicating malignant neoplasms. Blood 1963; 22: 73–81
   PubMed Web of Science ®Google Scholar
• Beamish M R, Jones P A, Trevett D, et al. Iron metabolism in Hodgkin's disease. Br J Cancer 1972; 26: 444–452
   PubMed Web of Science ®Google Scholar
• Bentley D P, Cavill I, Ricketts C. A method for the investigation of reticuloendothelial iron kinetics in man. Br J Haematol 1979; 43: 619–624
   PubMed Web of Science ®Google Scholar
• Zarrabi M D, Lysik R M, Zucker S. The anemia of chronic disorders: Studies of iron reutilization of the anaemia of experimental malignancy and chronic inflammation. Br J Haematol 1977; 35: 647–658
   PubMed Web of Science ®Google Scholar
• Konijn A M, Hershko C. Ferritin synthesis in inflammation I. Pathogenesis of impaired iron release. Br J Haematol 1977; 37: 7–16
   PubMed Web of Science ®Google Scholar
• Van Snick J L, Masson P L, Heremans J F. The involvement of lactoferrin in the hyposiderema of acute inflammation. J Exp Med 1974; 140: 1068–1084
   PubMed Web of Science ®Google Scholar
• Sztein M B, Vogel S N, Sipe J D, et al. The role of macrophages in the acute phase response: SAA inducer is closely related to lymphocyte activating factor and endogenous pyrogen. Cell Immunol 1981; 63: 164–176
   PubMed Web of Science ®Google Scholar
• Herskho C, Cook J F, Finch C A. Storage iron kinetics. VI. The effect of inflammation on iron exchange in the rat. Br J Haematol 1974; 28: 67–75
   PubMed Web of Science ®Google Scholar
• Firat D, Banzon J. Erythropoietic effect of plasma from patients with advanced cancer. Cancer Res 1971; 31: 1353–1358
   Google Scholar
• Dainiak N, Kulkarni V, Howard D, et al. Mechanism of abnormal erythropoiesis in malignancy. Cancer 1983; 51: 1101–1106
   PubMed Web of Science ®Google Scholar
• Zucker S, Lysik R M. Bone marrow erythropoiesis in anemia of inflammation. J Lab Clin Med 1974; 84: 620–631
   PubMed Web of Science ®Google Scholar
• Lukens J N. Control of erythropoiesis in rats with adjuvant-induced inflammation. Blood 1973; 41: 37–44
   PubMed Web of Science ®Google Scholar
• Alexanian R. Erythropoietin excretion in hemolytic anemia and in the hypoferremia of chronic disease. Blood 1972; 40: 946–951
   Web of Science ®Google Scholar
• Zucker S, Lysik R M, Friedman S. Diminished bone marrow responsiveness to erythropoietin in myelophthisic anemia. Cancer 1976; 37: 1308–1315
   PubMed Web of Science ®Google Scholar
• Zucker S, Lysik R M, DiStefano J. Pathogenesis of anemia in rats with Walker-256 carcinosarcoma. J Lab Clin Med 1977; 90: 502–511
   PubMedGoogle Scholar
• Chandler F W, Jr, Fletcher O J, Jr. Effect of a transplantable lymphoid tumor (Olson) on erythropoiesis and erythrocyte survival. Avian Dis 1973; 17: 737–742
   PubMed Web of Science ®Google Scholar
• DeGowin R L, Gibson D P, Knapp S A, et al. Tumor induced suppression of marrow stromal colonies. Ext Hematol 1981; 9: 811–819
   PubMed Web of Science ®Google Scholar
• DeGowin R L, Gibson D P, Knapp S A. Prostaglandin E and the erythropoietic and stromal insufficiency induced by extra-medullary tumor. J Lab Clin Med 1981; 98: 217–226
   PubMedGoogle Scholar
• Rossi G B, Migliaccio A R, Miggliaccio G, et al. In vitro interactions of PGE and cAMP with murine and human erythroid precursors. Blood 1980; 56: 74–479
   PubMed Web of Science ®Google Scholar
• Freedman M L, Marcus D L. Anemia and the elderly: Is it physiologic or pathologic. Am J Med Sci 1980; 280: 81–85
   PubMed Web of Science ®Google Scholar
• Vaughan J M, Oxon D M. Leukoerythroblastic anemia. J Pathol Bacteriol 1936; 42: 541–550
   Google Scholar
• Zucker S, Lysik R M, DiStefano J F. Cancer cell inhibition of erythropoiesis. J Lab Clin Med 1980; 95: 770–782
   Google Scholar
• Sjogren V, Brandt L. Erythropoiesis in patients with bone marrow metastases. Acta Med Scand 1974; 195: 325–328
   PubMed Web of Science ®Google Scholar
• Zucker S, Lysik R M. Cancer induced cytolysis of normal bone marrow cells. Nature 1977; 265: 736–737
   PubMed Web of Science ®Google Scholar
• DiStefano J F, Beck G, Lane B, et al. The role of rat tumor membrane bound serine proteases in tumor induced target cytolysis. Cancer Res 1982; 42: 207–218
   PubMed Web of Science ®Google Scholar
• Hoffman R, Kopel S, Hsu S D, et al. T cell chronic lymphocytic leukemia: Presence in bone marrow and peripheral blood of cells that suppress erythropoiesis in vitro. Blood 1978; 52: 255–260
   PubMed Web of Science ®Google Scholar
• Mangan K F, Chikkappa G, Farley P C. T gamma (Tγ) cells suppress growth of erythroid colony-forming units in vitro in the pure red cell aplasia of B-cell chronic lymphocytic leukemia. J Clin Invest 1982; 70: 1148–1156
   PubMed Web of Science ®Google Scholar
• Mangan K F, Hartnett M E, Matis S A, et al. Natural killer cells suppress human erythroid stem cell proliferation in vitro. Blood 1984; 63: 260–269
   PubMed Web of Science ®Google Scholar
• Meyer C E, Chabner B A, DeVita V T, et al. Bone marrow involvement in Hodgkin's disease: Pathology and response to MOPP chemotherapy. Blood 1974; 44: 197–204
   PubMed Web of Science ®Google Scholar
• Rodriguez-Kraul R, Hortobagy G N, Buzdar A U, et al. Cancer chemotherapy for breast cancer metastatic to bone marrow. Cancer 1981; 48: 227–232
   PubMed Web of Science ®Google Scholar
• Cline M J, Herman S P, Golde D W. Inhibitors of myelopoiesis. Transplan Proc 1978; 10: 99–102
   PubMed Web of Science ®Google Scholar
• Broxmeyer H E, Bognacki J, Dorner M H, et al. The identification of leukemia associated inhibitory activity (LIA) as acidic isoferritins: A regulatory role for acidic isoferritins in the production of granulocytes and macrophages. J Exp Med 1981; 153: 1426–1444
   PubMed Web of Science ®Google Scholar
• Broxmeyer H E, Smithyman A, Eger R E, et al. Identification of lactoferrin as the granulocyte-derived inhibitor of colony-stimulating activity production. J Exp Med 1978; 148: 1052–1067
   PubMed Web of Science ®Google Scholar
• Austin T, Ma A, Datta M C, et al. Suppression of mouse erythroid colony formation of L1210 leukemia cells. Exp Hematol 1979; 7: 63–73
   PubMed Web of Science ®Google Scholar
• Quesenberry P J, Rappaport J M, Fountebaroni A, et al. Inhibition of normal murine hematopoiesis by leukemic cells. N Engl J Med 1978; 299: 71–75
   PubMed Web of Science ®Google Scholar
• Olofsson T, Cline M J. Inhibitor of hematopoietic cell proliferation derived from a human leukemic cell line. Blood 1978; 51: 143–152
   Google Scholar
• Zucker S, Michael M, Lysik R M, et al. Lipoprotein inhibitor of bone marrow cells in tumor bearing rats. Cell Tissue Kinet 1979; 12: 393–404
   PubMedGoogle Scholar
• Yi P I, Beck G, Zucker S. Membrane receptors for very low density lipoprotein (VLDL) inhibitor of lymphocyte proliferation. Blood 1981; 57: 1055–1064
   PubMed Web of Science ®Google Scholar
• Roodman G D, Horadam V M, Wright T L. Inhibition of erythroid colony formation by autologous bone marrow adherent cells from patients with anemia of chronic disease. Blood 1983; 406: 412–417
   Google Scholar
• Hyman G, Gellhorn A, Harvey J L. Studies on the anemia of disseminated neoplastic disease. II. Study of the life span of the erythrocyte. Blood 1956; 11: 618–626
   PubMed Web of Science ®Google Scholar
• Minna J D, Bunn P A. Paraneoplastic syndromes. Cancer. Principles and Practice of Oncology, V T DeVito, S Hellman, S A Rosenberg. Lippincott, Philadelphia 1982; 1476–1517
   Google Scholar
• Brain M C, Azzapardi G, Baker R I, et al. Microangiopathic hemolytic anemia and mucin-forming adenocarcinoma. Br J Haematol 1970; 18: 183–190
   PubMed Web of Science ®Google Scholar
• Antman K W, Skarin A T, Mayer R J, et al. Microangiopathic hemolytic anemia and cancer. A review. Medicine 1979; 58: 377–384
   PubMed Web of Science ®Google Scholar
• Lohrmann H P, Adam W, Heymer B, et al. Microangiopathic hemolytic anemia in metastatic cancer. Report of 8 cases. Ann Int Med 1973; 76: 368–375
   Google Scholar
• Kressel B R, Ryan K P, Duong A T, et al. Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma. Cancer 1981; 48: 1738–1745
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M, et al. The French-American-British (FAB) Co-operative group-Proposal for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–196
   PubMed Web of Science ®Google Scholar
• Degnan T, Weiselberg L, Schulman P, et al. Dysmyelopoietic syndrome. Current concepts. Am J Med 1984; 76: 122–128
   PubMed Web of Science ®Google Scholar
• Rosenthal D S, Moloney W C. Refractory dysmyelopoietic anemia and acute leukemia. Blood 1984; 63: 314–318
   PubMed Web of Science ®Google Scholar
• Streuli R A, Testa J R, Vardiman J W, et al. Dysmyelopoietic syndrome: Sequential clinical and cytogenetic studies. Blood 1980; 55: 636–644
   PubMed Web of Science ®Google Scholar
• Castaigne S, Daniel M T, Tilly H, et al. Does treatment with Ara-C in low dosage cause differentiation of leukemic cells. Blood 1983; 62: 85–86
   PubMed Web of Science ®Google Scholar